Table. 2 Clinicopathological characteristics and outcomes of the external ESD test cohort (n = 35)
Variable | Total (n = 35) | Surgery group (n = 18) | Surveillance group (n = 17) |
|---|---|---|---|
Age (years, mean ± SD) | 66.00 ± 6.97 | 65.11 ± 5.20 | 66.94 ± 8.52 |
Sex (Male, %) | 25 (71.4%) | 14 (77.8%) | 11 (64.7%) |
Tumor size (mm) | 23.00 ± 16.06 | 25.94 ± 16.80 | 19.88 ± 15.11 |
Depth of invasion | |||
MM | 12 (34.3%) | 5 (27.8%) | 7 (41.2%) |
SM1 (≤200 µm) | 9 (25.7%) | 6 (33.3%) | 3 (17.6%) |
SM2 (>200 µm) | 14 (40.0%) | 7 (38.9%) | 7 (41.2%) |
Differentiation | |||
Well | 28 (80.0%) | 15 (83.3%) | 13 (76.5%) |
Moderate | 5 (14.3%) | 2 (11.1%) | 3 (17.6%) |
Poor | 2 (5.7%) | 1 (5.6%) | 1 (5.9%) |
Lymphovascular invasion (LVI) | 13 (37.1%) | 7 (38.9%) | 6 (35.3%) |
Tumor budding | |||
BD1 (0–4 buds) | 28 (80.0%) | 15 (83.3%) | 13 (76.5%) |
BD2 (5–9 buds) | 5 (14.3%) | 2 (11.1%) | 3 (17.6%) |
BD3 (≥10 buds) | 2 (5.7%) | 1 (5.6%) | 1 (5.9%) |
Positive margin (horizontal and/or vertical) | 23 (65.7%) | 12 (66.7%) | 11 (64.7%) |
Lymph node metastasis (LNM) | 4 (11.4%) | 4 (22.2%) | 0 |
